Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm currently has a $9.75 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 11.56% from the stock’s current price.

According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “

A number of other analysts also recently weighed in on ADAP. Cowen and Company reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Adaptimmune Therapeutics PLC has a consensus rating of “Hold” and an average target price of $12.38.

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) traded up 0.46% on Wednesday, hitting $8.74. 224,342 shares of the stock were exchanged. Adaptimmune Therapeutics PLC has a 12 month low of $3.76 and a 12 month high of $9.29.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.24). The firm had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. On average, equities research analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Adaptimmune Therapeutics PLC (ADAP) Upgraded at Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/04/adaptimmune-therapeutics-plc-adap-upgraded-at-zacks-investment-research.html.

Several large investors have recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. purchased a new stake in Adaptimmune Therapeutics PLC during the 1st quarter valued at about $120,000. KCG Holdings Inc. purchased a new stake in Adaptimmune Therapeutics PLC during the 1st quarter valued at about $133,000. Monashee Investment Management LLC purchased a new stake in Adaptimmune Therapeutics PLC during the 1st quarter valued at about $138,000. OxFORD Asset Management LLP purchased a new stake in Adaptimmune Therapeutics PLC during the 2nd quarter valued at about $156,000. Finally, Paloma Partners Management Co purchased a new stake in Adaptimmune Therapeutics PLC during the 1st quarter valued at about $165,000. 68.01% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.